Canada approves Cardiac Science's Powerheart:
This article was originally published in Clinica
Cardiac Science has received the go-ahead to market its Powerheart hospital bedside defibrillator-monitor in Canada. The fully automatic device detects the onset of a life-threatening arrhythmias and delivers defibrillation in seconds without the aid of hospital staff. The product is already cleared for sale in Australia, Europe and in the US. The Irvine, California-based company says it began marketing the device in early 2000 since when, it has generated around $4.2 million in revenue based on the sale of 734 Powerheart systems and related accessories.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.